SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

JENBURKT PHARMACEUTICALS

BSE: 524731 29 Jun 2025
Healthcare
₹ 1300
Jenburkt Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.

JENBURKT PHARMACEUTICALS - Share Price & Details

Market Cap
₹574.0
High /Low
1,375 / 816.0
Stock P/E
17.9
Book Value
₹389.0
Dividend Yield
1.18
ROCE
27.7
ROE
₹20.2
Face Value
10.0
PEG Ratio
1.08
EVEBITDA
₹11.7
Debt
3.89
CMP / FCF
59.7
Debt to equity
₹0.02
NP Ann
32.1
High price all time
1,375
Piotroski score
₹6.0
Graham Number
798.0
No. Eq. Shares
0.44
Net CF
₹3.24
Net profit
32.1
Price to book value
3.34
Interest Coverage
₹98.6
Low price all time
13.4
Industry PE
32.0
Reserves
₹167
Free Cash Flow
₹8.20

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
JENBURKT PHARMACEUTICALS LTD.NANANANA574.017.9
Prevest Denpro LimitedNANANANA57031.4
MEDICAMEN BIOTECH LTD.NANANANA56385.8

Peer Comparison Chart


About JENBURKT PHARMACEUTICALS

Jenburkt Pharmaceuticals Ltd., with Security Code 524731, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Are Jenburkt Pharma latest results good or bad?

(07 Jun 2025)
Jenburkt Pharmaceuticals reported a flat financial performance for the quarter ending March 2025, with net sales growth of 11.28% and net...
Read more →

Has Jenburkt Pharma declared dividend?

(06 Jun 2025)
Yes, Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend, with an ex-date of July 23, 2024. Despite this significant dividend announcement,...
Read more →

Jenburkt Pharma Standalone March 2025 Net Sales at Rs 41.05 crore, up 5.68% Y-o-Y

(23 May 2025)
Quarterly Net Profit at Rs. 8.54 crore in March 2025 up 8.3% from Rs. 7.88 crore in March 2024. EBITDA stands at Rs. 12.74 crore in March...
Read more →

Jenburkt Pharmaceuticals standalone net profit rises 8.38% in the March 2025 quarter

(21 May 2025)
Sales rise 5.69% to Rs 41.05 crore. Net profit of Jenburkt Pharmaceuticals rose 8.38% to Rs 8.54 crore in the quarter ended March 2025 as against Rs 7.88...
Read more →

Jenburkt Pharmaceuticals Reports Flat Financial Performance Amid Rising Non-Operating Income in May 2025

(20 May 2025)
Jenburkt Pharmaceuticals announced its financial results for the quarter ending March 2025 on May 20, 2025. The company reported its highest...
Read more →

Jenburkt Pharmaceuticals Adjusts Valuation Amidst Mixed Financial Performance and Stabilizing Trends

(19 May 2025)
Jenburkt Pharmaceuticals has recently experienced a score adjustment reflecting changes in its financial metrics. The stock's valuation grade has shifted,...
Read more →